BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30874560)

  • 1. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
    Peng Y; Liao Q; Tan W; Peng C; Hu Z; Chen Y; Li Z; Li J; Zhen B; Zhu W; Li X; Yao Y; Song Q; Liu C; Qi X; He F; Pei H
    Nat Commun; 2019 Mar; 10(1):1224. PubMed ID: 30874560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
    Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
    Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.
    Gupta R; Somyajit K; Narita T; Maskey E; Stanlie A; Kremer M; Typas D; Lammers M; Mailand N; Nussenzweig A; Lukas J; Choudhary C
    Cell; 2018 May; 173(4):972-988.e23. PubMed ID: 29656893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BARD1 reads H2A lysine 15 ubiquitination to direct homologous recombination.
    Becker JR; Clifford G; Bonnet C; Groth A; Wilson MD; Chapman JR
    Nature; 2021 Aug; 596(7872):433-437. PubMed ID: 34321663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination.
    Zhu Q; Huang J; Huang H; Li H; Yi P; Kloeber JA; Yuan J; Chen Y; Deng M; Luo K; Gao M; Guo G; Tu X; Yin P; Zhang Y; Su J; Chen J; Lou Z
    Nat Commun; 2021 Nov; 12(1):6653. PubMed ID: 34789768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites.
    Hu Z; Mi S; Zhao T; Peng C; Peng Y; Chen L; Zhu W; Yao Y; Song Q; Li X; Li X; Jia C; Pei H
    EMBO J; 2020 Jun; 39(12):e104133. PubMed ID: 32347575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
    Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
    Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataxin-3 consolidates the MDC1-dependent DNA double-strand break response by counteracting the SUMO-targeted ubiquitin ligase RNF4.
    Pfeiffer A; Luijsterburg MS; Acs K; Wiegant WW; Helfricht A; Herzog LK; Minoia M; Böttcher C; Salomons FA; van Attikum H; Dantuma NP
    EMBO J; 2017 Apr; 36(8):1066-1083. PubMed ID: 28275011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
    Ozden O; Bishehsari F; Bauer J; Park SH; Jana A; Baik SH; Sporn JC; Staudacher JJ; Yazici C; Krett N; Jung B
    Sci Rep; 2016 May; 6():26273. PubMed ID: 27197561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
    Qu J; Sun W; Zhong J; Lv H; Zhu M; Xu J; Jin N; Xie Z; Tan M; Lin SH; Geng M; Ding J; Huang M
    J Cell Biol; 2017 Feb; 216(2):409-424. PubMed ID: 28122957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
    Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
    Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition.
    Zhou J; Nie RC; He ZP; Cai XX; Chen JW; Lin WP; Yin YX; Xiang ZC; Zhu TC; Xie JJ; Zhang YC; Wang X; Lin P; Xie D; D'Andrea AD; Cai MY
    Adv Sci (Weinh); 2023 Dec; 10(36):e2302494. PubMed ID: 37985839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
    Reilly NM; Yard BD; Pittman DL
    Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1.
    Vélez-Cruz R; Manickavinayaham S; Biswas AK; Clary RW; Premkumar T; Cole F; Johnson DG
    Genes Dev; 2016 Nov; 30(22):2500-2512. PubMed ID: 27940962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.